**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 66203

**Manuscript Type:** MINIREVIEWS

**Current status of non-surgical treatment of locally advanced pancreatic cancer**

Spiliopoulos S *et al*. Non-surgical treatment of locally advanced PC

Stavros Spiliopoulos, Maria Teresa Zurlo, Annachiara Casella, Letizia Laera, Giammarco Surico, Alessia Surgo, Alba Fiorentino, Nicola de'Angelis, Roberto Calbi, Riccardo Memeo, Riccardo Inchingolo

**Stavros Spiliopoulos,** 2nd Radiology Department, Interventional Radiology Unit, National and Kapodistrian University of Athens, Athens 12461, Greece

**Maria Teresa Zurlo, Riccardo Inchingolo,** Interventional Radiology Unit, “F. Miulli” Regional General Hospital, Acquaviva delle Fonti 70021, Italy

**Annachiara Casella, Riccardo Memeo,** Unit of Hepato-Pancreatic-Biliary Surgery, “F. Miulli” Regional General Hospital, Acquaviva delle Fonti 70021, Italy

**Letizia Laera, Giammarco Surico,** Department of Oncology, General Regional Hospital “F. Miulli”, Acquaviva delle Fonti 70021, Italy

**Alessia Surgo, Alba Fiorentino,** Department of Radiation Oncology, “F. Miulli” Regional General Hospital, Acquaviva delle Fonti 70021, Italy

**Nicola de'Angelis,** Unit of Minimally Invasive and Robotic Digestive Surgery, “F. Miulli” Regional General Hospital, Acquaviva delle Fonti 70021, Italy

**Roberto Calbi,** Department of Radiology, General Regional Hospital “F. Miulli”, Acquaviva delle Fonti 70021, Italy

**Author contributions:** Spiliopoulos S, Zurlo MT, Casella A, Laera L, Surico G, Surgo A, Fiorentino A, de'Angelis N, Calbi R, Memeo R and Inchingolo R contributed data collection and manuscript writing, data analysis, and review design and supervision; all authors equally contributed to this paper with the conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Corresponding author: Stavros Spiliopoulos, MD, PhD, Associate Professor,** 2nd Radiology Department, Interventional Radiology Unit, National and Kapodistrian University of Athens, 1st Rimini St, Chaidari, Athens 12461, Greece. stavspiliop@med.uoa.gr

**Received:** March 22, 2021

**Revised:** June 28, 2021

**Accepted: October 25, 2021**

**Published online:**

**Abstract**

Pancreatic cancer is the 7th leading cause of death due to cancer in industrialized countries and the 11th most common cancer globally, with 458918 new cases (2.5% of all cancers) and 432242 deaths (4.5% of all cancer deaths) in 2018. Unfortunately, 80% to 90% of the patients present with unresectable disease, and the reported 5-year survival rate range between 10% and 25%, even after successful resection with tumor-free margins. Systemic chemotherapy, radiotherapy, and minimally invasive image-guided procedures that have emerged over the past years, are used for the management of non-operable PC. This review focuses on currently available non-surgical options of locally advanced pancreatic cancer.

**Key Words:** Interventional radiology; Oncology; Radiotherapy; Pancreatic cancer; Ablation

Spiliopoulos S, Zurlo MT, Casella A, Laera L, Surico G, Surgo A, Fiorentino A, de'Angelis N, Calbi R, Memeo R, Inchingolo R. Current status of non-surgical treatment of locally advanced pancreatic cancer. *World J Gastrointest Oncol* 2021; In press

**Core Tip:** Currently available non-surgical treatment options for locally advanced pancreatic cancer include systemic chemotherapy, radiotherapy, and minimally invasive image-guided procedures. The latter have emerged over the past years and include radiofrequency, microwave ablation, laser ablation, cryoablation, irreversible electroporation, high intensity focused ultrasound, and trans-arterial embolization procedures. Although initial results were not deemed satisfactory, mainly due to unacceptable complication rates, cumulative experience and technological advances have led to the improvement of outcomes of image-guided procedures and their incorporation in the treatment algorithm.

**INTRODUCTION**

Pancreatic cancer (PC) is the 7th leading cause of death due to cancer in industrialized countries and the 11th most common cancer globally with 458918 new cases (2.5% of all cancers) and 432242 deaths (4.5% of all cancer deaths) in 2018[1]. Its incidence is variable among regions (age-standardized incidence highest in Europe: 7.7 per 100000 people and lowest in Africa: 2.2 per 100000 people) and is expected to increase[1,2]. Both incidence and mortality of the disease correlate with increasing age and male gender[2].

Modifiable risk factors include alcohol (increased risk high alcohol consumption > three drinks per day, but no association with low-to-moderate alcohol intake), smoking (relative risk 1.74 for current and 1.2 for former smokers; risk persists for at least 10 years after cessation), obesity [body mass index (BMI): 25.0-29.9 kg/m2 or BMI ≥ 30 kg/m2 in early adulthood], dietary factors (red meats, processed meats, cholesterol, foods containing nitrosamines) and exposure to metalworking, pesticides, cadmium, and arsenic[2,3]. Non-modifiable risk factors are gender (global incidence 5.5/100000 for men and 4.0/100000 for women), age (> 50 years), ethnicity (significantly higher in black people than any other racial group), diabetes mellitus (1.8-fold risk increase), family history (double risk when at least two first-degree relatives have PC and 32-fold higher in kindreds with three or more first-degree relatives) genetic factors (10% of patients have some kind of germ-line mutation), chronic infections (*Helicobacter pylori*), non-O blood group and chronic pancreatitis (1.8% patients longstanding pre-existing chronic pancreatitis will develop PC within 10 years from diagnosis and 4% after 20 years)[2,4].

PC symptomatology is frequently non-specific (abdominal pain, jaundice, pruritus, dark urine, and acholic stools, anorexia, early satiety, dyspepsia, nausea, and eventually weight loss), while the early-stage disease remains frequently asymptomatic and most patients present at an advanced stage with poor prognosis[5,6]. Early detection could reduce mortality and screening of selected sub-groups such as those with a family history), using blood markers could be deemed beneficial in the future. Nevertheless, screening of the general population is not currently recommended[7,8]. Diagnosis and staging include imaging modalities such as contrast-enhanced, triphasic pancreatic computed tomography (CT) protocol, magnetic resonance imaging. Endoscopic ultrasound-guided fine-needle aspiration is indicated for cytological confirmation with a sensitivity of approximately 80%), while cancer antigen 19-9 assists in the confirmation of diagnosis, prediction of prognosis, and recurrence following surgery[7].

Surgical resection remains the only curative therapy for PC. However, 80% to 90% of the patients present with unresectable tumors and the reported 5-year survival rates are low, ranging between 10% and 25%, even after successful resection with tumor-free margins[2,9]. Over the past years, alongside with systemic chemotherapy and radiotherapy (RT), minimally invasive image-guided procedures have emerged for the management of non-operable or recurrent locally advanced PC. These include ablative modalities such as radiofrequency ablation (RFA), microwave ablation (MWA), laser ablation, cryoablation (CA), reversible electrochemotherapy (ECT) and irreversible electroporation (IRE), and high intensity focused ultrasound, while trans-arterial embolization procedures have also been suggested and investigated[10-12]. Following the initially non-satisfactory results, which were correlated with unacceptable complication rates, outcomes of minimally-invasive image-guided procedures were significantly improved, mainly due to the cumulative experience, and technological advances of the devices used, and their incorporation in the treatment algorithm for PC has been gradually accepted in specialized centers[10].

**ABLATIVE TECHNIQUE**

Patients with stable or partial response RECIST (response evaluation criteria in solid tumors) disease following neoadjuvant therapy, and not eligible for surgery should be considered as potential candidates for ablative therapies[13-16]. Ablative treatment can be divided into thermal (RFA, CA, MWA) and non-thermal (RE, IRE).

***Thermal ablation***

RFA uses needle electrodes to apply high-frequency alternating current to solid tumors. This process generates high temperatures, resulting in thermal coagulation, necrosis, and protein denaturation within the tumor[15]. It can be performed during laparotomy, percutaneously, or using endoscopic ultrasound. Usually, RFA is adopted for tumor debulking rather than complete ablation, as a safety margin of at least 5 mm from the ablation zone is necessary to avoid thermal damage to vital structures. This treatment is also contraindicated in small tumors with a perivascular growth pattern[17]. Early studies investigating the efﬁcacy and safety of RFA in the treatment of LAPC reported high rates of morbidity (4%-37%) and mortality (0%-25%) due to thermal injury to bile ducts, pancreatic duct, duodenum, vital vessels, and heat-sink effect, resulting in incomplete tumor ablation. Recent literature shows an improved overall survival (OS) ranging between 19.0 and 25.6 mo when combining RFA with chemotherapy[17] by optimizing ideal parameters for temperature range (< 90 degrees), treatment time, and probe placement[15].

CA induces rapid argon-gas-based freezing and thawing of target lesions. The freeze-thaw cycles, based on the Joule-Thompson effect, cause cellular destruction by vascular-mediated cytotoxicity, endothelial damage, and cell death. CA with and without immunotherapy for LAPC treatment in term of OS was studied in a retrospective study: Median OS was higher in the cryoimmunotherapy (13 mo) and cryotherapy groups (7 mo) than in the chemotherapy group (3.5 mo; both *P* < 0.001) and was higher in the cryoimmunotherapy group than in the cryotherapy (*P* < 0.05) and immunotherapy groups (5 mo; *P* < 0.001)[15].

MWA promotes tissue coagulation by the oscillation of water molecules, ultimately generating tissue necrosis. This technique has advantages over RFA in the ease of setup and larger ablation zones in a shorter period but recent literature on the use of MW ablation in PC with survival data is very limited[15].

***Non-thermal ablation***

IRE uses ultrashort high voltage direct current pulses to create an electric ﬁeld across the cell membrane. This process disrupts membrane homeostasis and irreversibly alters transmembrane potential, which activates the apoptotic pathway and leads to cell death (Figure 1). IRE has the unique ability to preserve the extracellular matrix, critical vessel structures, bile ducts, intestines and minimize heat-sink effects resulting in potentially incomplete ablation. The technology is commercially available (NanoKnife; Angiodynamics Latham, NY, United States) with 510(k) clearance by the Food and Drug Administration (FDA) for ablation of soft tissue tumors[15,18]. In addition to its cytoreductive abilities, the evidence is emerging on IRE’s capability to induce systemic immunomodulation through active *in vivo* vaccination against PC cells. IRE induces a systemic immune response following apoptosis and necrosis of tumor cells with the release of antigens and damage-associated molecular pattern molecules (DAMPs). These DAMPs promote the maturation of dendritic cells and other antigen-presenting cells that can subsequently take up the activation of lymph nodal T-cells potentially inducing a durable antitumor T-cell response. This response could then lead to regression in distant metastases, a process known as the “abscopal effect”. These effects in combination with immunotherapy may offer a new treatment paradigm for tumors with low immunogenic potential, like pancreatic ductal adenocarcinoma[16]. IRE can be performed during open or laparoscopic surgical exploration or percutaneous procedure with CT guidance. For IRE, 2-6 electrodes are typically placed around the tumor, with a maximum spacing of 2.0-2.5 cm, using image guidance and an upper limit of 5 cm in tumor diameter is highly recommended[17]. Given the high-risk proﬁle of pancreatic IRE procedures, it is important to consider absolute and relative contraindications and to carefully assessed patients for treatment: it is advised to exclude patients with irreversible bleeding disorders, epilepsy, or any other unstable condition that precludes general anesthesia like patients with a past medical history of cardiac disease (*i.e.*, cardiac arrhythmia, implantable cardioverter defibrillator, pacemaker) given the risk of inducing cardiac arrhythmias when applying the electrical pulses[18]; pervasive involvement of the duodenum is considered an absolute contra-indication; if the patient is affected by biliary obstruction, adequate biliary drainage must be guaranteed prior to treatment and if the tumor is closed to the common bile duct it is highly recommended to ensure biliary protection prior to treatment, as post-IRE swelling can impede passage through the central bile ducts; if a patient suffers from a partially occluded portal vein prior to IRE, portal vein stenting should be performed to prevent acute complete occlusion due to postprocedural swelling. Most frequent adverse events comprise GI-related symptoms including pain, diarrhea, nausea, vomiting, loss of appetite, and delayed gastric emptying[16]. Previous cohort studies report heterogeneous outcomes, with median OS rates varying between 15-32 mo when combining IRE with systemic treatment. A recent systematic review by Moris *et al*[16] shows an overview of all studies that have utilized IRE for LAPC, with a median OS following IRE between 7 and 27 mo. This variance may be due to selection bias, the utilized IRE approach, the diverse LAPC tumor biology, personalized (neo-) adjuvant chemo- and/or RT protocols, performance status including comorbidities, and other interpersonal patient differences. In general, major complications (*e.g.*, portal vein thrombosis, bleeding, duodenal perforation) are reported in 0%-30% of patients, with mortality rates ranging between 0%-11%[17]. The average cumulative morbidity for surgical and percutaneous IRE was 36% *vs* 24%, with an average periprocedural mortality rate of 2% *vs* 0%, respectively[16].

Reversible ECT is a new non-thermal ablation technique that avoids possible thermal injury to the peripancreatic vessels like portal mesenteric vein combining the use of chemotherapeutic drugs (bleomycin) with electric pulses for cell membrane electroporation. A transient cell membrane improve permeability is determined by electric pulses, permitting the exposure of the cell to chemotherapeutic drugs[19]. The procedure is divided into four steps: Laparotomy or laparoscopic or percutaneous approach and intraoperative ultrasound to confirm that the pancreatic tumor was unresectable and to exclude distant metastases, needle insertion, bleomycin infusion and electroporation. Eight minutes after the bleomycin infusion, electric pulses were applied and delivered using four single long needle electrodes having 1.2 mm in diameter, and 3 or 4 cm active part. ECT was performed mostly in young patients (mean age, 63 years), with a good performance status and normal BMI. ECT was safe, according to the absence of acute intraoperative adverse effects related to electroporation and effects related to the bleomycin[19]. Nevertheless there is few studies regarding ECT in literatures[20,21] and additional studies should be carried out.

**INTRA-ARTERIAL THERAPIES**

Since the 1950s, regional intra-arterial chemotherapy (RIAC) was introduced in an attempt to increase cancer survival rates. Intra-arterial chemotherapy generates high drug concentrations in the target areas while maintaining low systemic drug levels. Clinical trials demonstrated that regional intraarterial infusion with Gemcitabine (GEM) improved the response and resectability rates for advanced PC and was well tolerated by patients[22,23]. In 2012, a systematic review and meta-analysis of six randomized controlled trials, comparing systemic chemotherapy, with RIAC, reported that the latter resulted in higher partial remission, clinical benefits and response rates with fewer complications including myelosuppression[24].

With regards to efficacy, it is known that the effect of chemotherapy is concentration-dependent, therefore intra-arterial local infusion which generates higher drug concentrations within targeted regions, could be proven more efficient. In fact, according to the results of two RCTs, RIAC improved the 1-year OS (41.2%-28.6%) compared with systemic chemotherapy[25,26].

Other Authors considered the use of RIAC as neoadjuvant regional chemotherapy with continuous infusion of GEM intending to improve resectability rates in case of locally advanced PC[27]. A study was carried out to investigate the prognostic factors in patients who received GEM-based intra-arterial infusion for advanced PC; young age, pretreatment CA19-9 value < 1000 U/mL, and tumor located at the head of the pancreas indicated better response to RIAC and improved survival[28].

A recent retrospective cohort study of 454 patients with advanced PC compared RIAC *via* angiographically placed celiac axis catheters *vs* isolated upper abdominal perfusion (upper abdominal perfusion with stop flow balloon catheters in the aorta and vena cava)[29]. The isolated perfusion group demonstrated superior survival compared to intra- arterial infusion (median survival rates: 12 and 8 mo in stage III; 8.5 and 7 mo in stage IV; respectively)[29].

Future perspectives in local chemotherapy include novel infusion techniques such as Trans-Arterial Micro-Perfusion (TAMP) using the RenovoCath catheter (RenovoRx, Inc.) which was recently approved by the FDA. The TAMP procedure involves arterial segment isolation using proximal and distal occlusion balloons generating increased intra-arterial luminal pressure above the interstitial pressure and forcing the drug across the arterial wall within the tumoral tissue. The specific catheter has the potential to deliver higher drug concentrations within the tumor, while limiting systemic exposure. The TIGeR-PaC Phase III randomized clinical trial is currently enrolling patients with unresectable LAPC to investigate TAMP *vs* systemic chemotherapy. The goal of the trial is to prove extended median survival and improved quality of life through targeted delivery of therapy. In Phase, I/II studies, TAMP resulted in over two years survival in more than half the patients. The TIGeR-PaC trial, currently includes approximately 30 active clinical sites, and is expected to involve 200 participants in 40 centers in the United States and Europe (clinicaltrials.gov NCT03257033).

**ONCOLOGY**

LAPC is in general considered incurable and the management remains unclear and controversial. Treatment includes chemotherapy, which can have a potential role as neoadjuvant treatment or in combination with RT on a case-based approach. The aim is to control disease progression, palliation, and improvement of OS. Patients with LAPC have a poor prognosis, with a median OS of 12-14 mo following systemic therapies[14]. The first step before choosing the appropriate treatment plan is the assessment of the patient’s performance status. Patients with locally advanced disease received therapies based on their performance. Patients with a poor performance status are candidates to single-agent chemotherapy or palliative radiation therapy or best supportive care; patients with a good performance status can be considered for a more intensive oncological strategy as chemotherapy or chemoradiation[30].

Formerly, standard treatment included GEM for six months. However, in 2011, the Eastern cooperative Oncology group reported improved OS with the addition of radiation therapy (for a total of 50.4 Gy) to GEM[31].

In 2016, Suker *et al*[32] conducted a patient-level meta-analysis of 11 studies (315 patients) indicating that LAPC patients treated with FOLFIRINOX demonstrated a median OS of 24.2 mo, which was significantly higher compared to that achieved by GEM therapy (6-13 mo).

While systematic chemotherapy has become the standard for patients with LAPC, surgery remains the only potentially curative therapy. Therefore, the development of a new neoadjuvant treatment that improves survival rate is of the utmost importance. Neoadjuvant chemotherapy should aim in a possible resection, or radiation therapy or IRE. Clinicians and researchers should investigate cancer biology and invest to define predictive and prognostic factors, patients-related features, and biological criteria to identify patients that would benefit from aggressive surgery or chemotherapy and chemoradiation[33].

When surgery is not possible after induction chemotherapy, chemoradiotherapy (intensity modulated radiation therapy or stereotactic body radiation therapy), is a possible option to incite tumor shrinkage and enable secondary resection in a small percentage of patients, while palliation of cancer-related pain is also a significant goal in unresectable tumors. The LAP07 phase III randomized controlled trial was designed to investigate the effect of chemoradiotherapy and erlotinib in the OS of patients with LAPC controlled after 4 mo of GEM-based induction chemotherapy. Unfortunately, both chemoradiotherapy and erlotinib did not provide any benefit in patients with LAPC[34].

On the other hand, in an updated 2018 review and meta-analysis of 41 studies (1018 patients receiving consolidation chemoradiation after induction chemotherapy and 954 patients receiving chemotherapy alone) the authors noted a significant survival benefit for chemoradiation after induction chemotherapy in cases in which chemotherapy lasted for a period of at least 3 mo[35].

Currently, according to the results of the SCALOP multicenter, open-label, randomized, two-arm, phase 2 trial, a capecitabine-based regimen should be preferred over a GEM-based regimen in the context of consolidation chemoradiotherapy after a course of induction chemotherapy for locally advanced PC[36].

Only recently, novel minimally invasive approaches, such as IRE, have been evaluated for treatment of LAPC after induction chemotherapy. The PANFIRE-2 multicenter, prospective, single-arm study investigated the safety and efficacy of percutaneous CT-guided IRE alone or after induction chemotherapy with GEM alone or FOLFIRINOX. In total 50 patients were enrolled (40 with LAPC and 10 with local recurrence) and target median OS was exceeded in patients with LAPC (17 mo) and those with local recurrence (16 mo). Notably, 14 minor and 21 major complications occurred, while one probable IRE-related death was reported[14]. Some data suggest the potential role of IRE after FOLFIRINOX chemotherapy as better results have been noted in specific subgroups of patients. IRE could be considered as a less invasive potentially curative approach for LAPC[37]. Nevertheless, randomized clinical trials are necessary to provide comparative data regarding the efficacy of these three methods.

**RT**

About 80%-90% of the patients with PC, present with locally advanced disease at diagnosis and consequently a very poor prognosis of less than 5% OS at 5-years[38,39]. In this group of patients, RT associated with systemic therapy plays a crucial role in achieving satisfactory local control (LC). As noted above, the LAP 07 phase III study failed to demonstrate any significant advantage on OS, but a substantially decreased local progression rate (32% *vs* 46%, *P* = 0.03) for chemoradiotherapy was noted, without increase in grade 3 to 4 toxicity (except for nausea)[34]. In this context, for patients demonstrating good performance status, the aim of combining RT with systemic therapy is to provide satisfactory LC and avoid or delay local disease progression. However, it is crucial that during RT a higher radiation dose should be delivered to the tumor, limiting doses to healthy tissue.

Conventionally, the standard RT dose has been set around of 50-54 Gy administered over 6 wk using the 3D conformal radiation technique (3D-CRT), a dose initially established on the tolerance of large-field radiation to organ at risks. However, these doses showed a limited LC of the disease, while higher doses often induce treatment-related toxicity that can significantly affect the patient’s quality of life[40].

Over the past decade, modern technological advances such as intensity-modulated RT (IMRT), the introduction of respiratory management methods and improved imaging guidance during therapy, have enabled dose-escalation therapy and facilitated the possibility to reduce treatment volumes, to improve ablative doses to the tumor and consequently clinical outcomes, concurrently reducing treatment toxicity[41]. In fact, like other mobile tumors, pancreatic tumors require assessment of respiratory movements, while RT dosimetry is additionally complicated by the presence of nearby hollow digestive organs.

In a 2015 systematic review, 13 IMRT studies were analyzed and compared with 7 3D-CRT series, in order to compare toxicity and tumor outcomes between these two different RT-techniques for the management of LAPC. Even though no differences in terms of OS and PFS were obtained, IMRT was correlated with reduced risk of side effects[42]. Surely, the absence of OS advantage could be explained by the conventionally delivered dose, which is not sufficient to efficiently control the disease[43].

In a study published by Krishnan *et al*[44], patients who received an intensified dose with a biological effective dose (BED) > 70 Gy demonstrated higher OS compared to those who received a standard dose BED ≤ 70 Gy. In this scenario, in which the main limitation remains the risk of severe intestinal toxicity, stereotactic body RT (SBRT) has also been largely explored as a potentially effective treatment for patients with LAPC (Figure 2)[45-61]. Of note, poor prognosis related to these tumors has motivated physicians to limit the number of RT sessions and concentrate treatment within one to two weeks, thereby reducing the period of chemotherapy interruption and increasing patient’s compliance.

According to recent data on SBRT treatment for LAPC, a large heterogeneity in total dose prescription and fractionations was reported. Generally, the total doses used ranged from 30 Gy to 45 Gy in 3-5 fractions resulting in effective biological dose (BED) superior to 60 Gy (assuming an α/β = 10) in most of the cases[46-60]. This higher dose/fraction can theoretically produce enhanced cell destruction than conventional fractionation[62]. Due to the aggressiveness of the disease which causes a rapid evolution of the metastatic sites, OS is not greatly decreased in SBRT series.

Despite satisfactory LC and median freedom from local progression rates of approx. Eighty percent at 1 year, and very low acute toxicity obtained by SBRT single fraction treatments (25 Gy/1 fr)[45,47,48,51,52], high rates of late toxicity have limited the use of this approach. Therefore, multi-fraction treatment schemes are preferably used. In a retrospective cohort of 167 LAPC patients, 45% of whom were treated in single fraction SBRT and 54% in five-fraction SBRT, five-fraction protocol showed significantly lower gastrointestinal toxicity compared to the single fraction treatment. However, good LC rate was noted in both groups[54].

Similar conclusions were drawn following several retrospective studies that acknowledged the benefit in terms of reduced toxicity when multi-fractionated (3-5 fractions) RT regimens were applied compared to single fraction treatment, while obtaining the same efficacy in terms of LC[49,50,52,53,55-57]. All patients investigated in these studies, received systemic therapy (mainly GEM) during different time points of SBRT treatment (before, after or both before and after SBRT) and therapeutic schemes were variable based on the patients’ clinical status and the grade of the disease. Notably, the indication for intensified local treatment using SBRT in LAPC patients may be abruptly compromised due to the high metastatic potential of the disease.

Only few, non-randomized, retrospective studies compared SBRT and conventional fractionated RT[63] in the local advanced PC curative or neo-adjuvant setting. SBRT was associated with significantly improved OS compared to conventional fractionated RT. Additionally, SBRT was associated with significantly increased rates of pathological complete response and margin-negative resection in neo-adjuvant setting. These are promising results and provide the basis for consideration for prospective validation.

However, the indication for SBRT in order to intensify local treatment may be affected by the high metastatic potential of the disease.

**CONCLUSION**

The prognosis of LAPC remains poor although recent advancements in multimodality treatment seem to provide some improvement in clinical outcomes. Combined modality treatment using systemic chemotherapy, minimally invasive image-guided procedures and RT are currently under investigation. Neoadjuvant chemotherapy could be used to enable curative surgical resection, radiation therapy, or ablation. SBRT may be employed to obtain satisfactory LC and reduce side effects. Mounting experience with percutaneous thermal ablation and IRE provides superior outcomes with less complications. Considering the currently unsatisfactory results in terms of OS improvement, different treatment options should be investigated to optimize therapy. As the pathogenesis of LAPD is multifactorial and has been associated with genetic factors (mainly germ-line BRCA2 gene mutations, but also various syndromes such as the Lynch syndrome, hereditary breast and ovarian cancer syndrome, familial adenomatous polyposis and Li-Fraumeni syndrome) environmental factors (obesity, smoking habit, diabetes, alcohol consumption, dietary factors such as red meat consumption, and occupational exposure to nickel cadmium and arsenic, and the human microbiome), future treatment directions should focus on the investigation of these factors to provide personalized therapeutic schemes and improve survival[2,64,65].

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Rawla P**, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World J Oncol* 2019; **10**: 10-27 [PMID: 30834048 DOI: 10.14740/wjon1166]

3 **Shin EJ**, Canto MI. Pancreatic cancer screening. *Gastroenterol Clin North Am* 2012; **41**: 143-157 [PMID: 22341255 DOI: 10.1016/j.gtc.2011.12.001]

4 **American Cancer Society**. Cancer Facts and Figures 2014. [cited 20 March 2021]. In: American Cancer Society [Internet]. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2014.html

5 **Guo XZ**, Cui ZM, Liu X. Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer. *World J Gastrointest Oncol* 2013; **5**: 20-28 [PMID: 23556053 DOI: 10.4251/wjgo.v5.i2.20]

6 **Krech RL**, Walsh D. Symptoms of pancreatic cancer. *J Pain Symptom Manage* 1991; **6**: 360-367 [PMID: 1880437 DOI: 10.1016/0885-3924(91)90027-2]

7 **Cappelli G**, Paladini S, D'Agata A. [Tumor markers in the diagnosis of pancreatic cancer]. *Tumori* 1999; **85**: S19-S21 [PMID: 10235075]

8 **Rastogi T**, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, Sinha R. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. *Int J Epidemiol* 2008; **37**: 147-160 [PMID: 18094016 DOI: 10.1093/ije/dym219]

9 **Saif MW**. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. *JOP* 2007; **8**: 545-552 [PMID: 17873458]

10 **Ierardi AM**, Lucchina N, Bacuzzi A, Marco de C, Bracchi E, Cocozza E, Dionigi G, Tsetis D, Floridi C, Carrafiello G. Percutaneous ablation therapies of inoperable pancreatic cancer: a systematic review. *Ann Gastroenterol* 2015; **28**: 431-439 [PMID: 26424487]

11 **Tanaka T**, Sho M, Nishiofuku H, Sakaguchi H, Inaba Y, Nakajima Y, Kichikawa K. Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine. *AJR Am J Roentgenol* 2012; **198**: 1445-1452 [PMID: 22623561 DOI: 10.2214/AJR.11.8008]

12 **Das SK**, Wang JL, Li B, Zhang C, Yang HF. Clinical effectiveness of combined interventional therapy as a salvage modality for unresectable pancreatic carcinoma. *Oncol Lett* 2019; **18**: 375-385 [PMID: 31289509 DOI: 10.3892/ol.2019.10323]

13 **Lafranceschina S**, Brunetti O, Delvecchio A, Conticchio M, Ammendola M, Currò G, Piardi T, de'Angelis N, Silvestris N, Memeo R. Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. *Cancers (Basel)* 2019; **11** [PMID: 31684186 DOI: 10.3390/cancers11111718]

14 **Ruarus AH**, Vroomen LGPH, Geboers B, van Veldhuisen E, Puijk RS, Nieuwenhuizen S, Besselink MG, Zonderhuis BM, Kazemier G, de Gruijl TD, van Lienden KP, de Vries JJJ, Scheffer HJ, Meijerink MR. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. *Radiology* 2020; **294**: 212-220 [PMID: 31687922 DOI: 10.1148/radiol.2019191109]

15 **Narayanan G**, Ucar A, Gandhi RT, Nasiri A, Inampudi P, Wilson NM, Asbun HJ. Emerging Ablative and Transarterial Therapies for Pancreatic Cancer. *Dig Dis Interv* 2020; **4**: 389-339 [DOI: 10.1055/s-0040-1721415]

16 **Moris D**, Machairas N, Tsilimigras DI, Prodromidou A, Ejaz A, Weiss M, Hasemaki N, Felekouras E, Pawlik TM. Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. *Ann Surg Oncol* 2019; **26**: 1657-1668 [PMID: 30843163 DOI: 10.1245/s10434-019-07261-7]

17 **van Veldhuisen E**, van den Oord C, Brada LJ, Walma MS, Vogel JA, Wilmink JW, Del Chiaro M, van Lienden KP, Meijerink MR, van Tienhoven G, Hackert T, Wolfgang CL, van Santvoort H, Groot Koerkamp B, Busch OR, Molenaar IQ, van Eijck CH, Besselink MG; Dutch Pancreatic Cancer Group and International Collaborative Group on Locally Advanced Pancreatic Cancer. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. *Cancers (Basel)* 2019; **11** [PMID: 31336859 DOI: 10.3390/cancers11070976]

18 **Narayanan G**, Hosein PJ, Beulaygue IC, Froud T, Scheffer HJ, Venkat SR, Echenique AM, Hevert EC, Livingstone AS, Rocha-Lima CM, Merchan JR, Levi JU, Yrizarry JM, Lencioni R. Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. *J Vasc Interv Radiol* 2017; **28**: 342-348 [PMID: 27993507 DOI: 10.1016/j.jvir.2016.10.023]

19 **Casadei R**, Ricci C, Ingaldi C, Alberici L, Di Marco M, Guido A, Minni F, Serra C. Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results-a single-center experience. *Updates Surg* 2020; **72**: 1089-1096 [PMID: 32399592 DOI: 10.1007/s13304-020-00782-x]

20 **Jaroszeski MJ**, Gilbert RA, Heller R. In vivo antitumor effects of electrochemotherapy in a hepatoma model. *Biochim Biophys Acta* 1997; **1334**: 15-18 [PMID: 9042359 DOI: 10.1016/s0304-4165(96)00147-x]

21 **Girelli R**, Prejanò S, Cataldo I, Corbo V, Martini L, Scarpa A, Claudio B. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. *Radiol Oncol* 2015; **49**: 147-154 [PMID: 26029026 DOI: 10.1515/raon-2015-0013]

22 **Aigner KR**, Gailhofer S. Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer--a phase II study on 265 cases. *Anticancer Res* 2005; **25**: 4407-4412 [PMID: 16334117]

23 **Li Q**, Wang MQ, Duan LX, Song P, Ao GK. Regional arterial infusion chemothera-py with lipid emulsion as a solvent for the treatment of advanced pancreatic can-cer: A preliminary clinical study. *J Interv Radiol* 2009; **18**: 275-277

24 **Liu F**, Tang Y, Sun J, Yuan Z, Li S, Sheng J, Ren H, Hao J. Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials. *PLoS One* 2012; **7**: e40847 [PMID: 22815840 DOI: 10.1371/journal.pone.0040847]

25 **Aigner KR**, Gailhofer S, Kopp S. Regional *vs* systemic chemotherapy for advanced pancreatic cancer: a randomized study. *Hepatogastroenterology* 1998; **45**: 1125-1129 [PMID: 9756018]

26 **Hong GB**, Zhou JX, Liang BL. A Clinical Study on Continuous Transarterial Infusion Chemotherapy with Gemcitabine and 5-fluorouracil in Treating Patients with Advanced Pancreatic Carcinoma. *Cancer Prev* 2007; **33**: 54-56

27 **Davis JL**, Pandalai P, Ripley RT, Langan RC, Steinberg SM, Walker M, Toomey MA, Levy E, Avital I. Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial. *Trials* 2011; **12**: 129 [PMID: 21595953 DOI: 10.1186/1745-6215-12-129]

28 **Liu X**, Yang X, Zhou G, Chen Y, Li C, Wang X. Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma. *Medicine (Baltimore)* 2016; **95**: e3098 [PMID: 26986149 DOI: 10.1097/MD.0000000000003098]

29 **Aigner KR**, Gailhofer S, Selak E, Aigner K. Intra-arterial infusion chemotherapy *vs* isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients. *J Cancer Res Clin Oncol* 2019; **145**: 2855-2862 [PMID: 31506738 DOI: 10.1007/s00432-019-03019-6]

30 **National Comprehensive Cancer Network**. NCCN guideline version 1.2021 pancreatic cancer. [cited 20 March 2021]. In: National Comprehensive Cancer Network [Internet]. Available from: https://www.spg.pt/wp-content/uploads/Guidelines/NCCN/pancreatic.pdf

31 **Loehrer PJ Sr**, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd. Gemcitabine alone *vs* gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. *J Clin Oncol* 2011; **29**: 4105-4112 [PMID: 21969502 DOI: 10.1200/JCO.2011.34.8904]

32 **Suker M**, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. *Lancet Oncol* 2016; **17**: 801-810 [PMID: 27160474 DOI: 10.1016/S1470-2045(16)00172-8]

33 **Barcellini A**, Peloso A, Pugliese L, Vitolo V, Cobianchi L. Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress. *Onco Targets Ther* 2020; **13**: 12705-12720 [PMID: 33335406 DOI: 10.2147/OTT.S220971]

34 **Hammel P**, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Effect of Chemoradiotherapy *vs* Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. *JAMA* 2016; **315**: 1844-1853 [PMID: 27139057 DOI: 10.1001/jama.2016.4324]

35 **Chang JS**, Chiu YF, Yu JC, Chen LT, Ch'ang HJ. The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis. *Cancer Res Treat* 2018; **50**: 562-574 [PMID: 28602054 DOI: 10.4143/crt.2017.105]

36 **Mukherjee S**, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. *Lancet Oncol* 2013; **14**: 317-326 [PMID: 23474363 DOI: 10.1016/S1470-2045(13)70021-4]

37 **He C**, Sun S, Huang X, Zhang Y, Lin X, Li S. Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer. *Front Oncol* 2020; **10**: 622318 [PMID: 33604301 DOI: 10.3389/fonc.2020.622318]

38 **Varadhachary GR**, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. *Ann Surg Oncol* 2006; **13**: 1035-1046 [PMID: 16865597 DOI: 10.1245/ASO.2006.08.011]

39 **Worni M**, Guller U, White RR, Castleberry AW, Pietrobon R, Cerny T, Gloor B, Koeberle D. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. *Pancreas* 2013; **42**: 1157-1163 [PMID: 23867367 DOI: 10.1097/MPA.0b013e318291fbc5]

40 **Cattaneo GM**, Passoni P, Longobardi B, Slim N, Reni M, Cereda S, di Muzio N, Calandrino R. Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma. *Radiother Oncol* 2013; **108**: 66-71 [PMID: 23726116 DOI: 10.1016/j.radonc.2013.05.011]

41 **Garibaldi C**, Jereczek-Fossa BA, Marvaso G, Dicuonzo S, Rojas DP, Cattani F, Starzyńska A, Ciardo D, Surgo A, Leonardi MC, Ricotti R. Recent advances in radiation oncology. *Ecancermedicalscience* 2017; **11**: 785 [PMID: 29225692 DOI: 10.3332/ecancer.2017.785]

42 **Bittner MI**, Grosu AL, Brunner TB. Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer - a systematic review. *Radiother Oncol* 2015; **114**: 117-121 [PMID: 25497876 DOI: 10.1016/j.radonc.2014.11.043]

43 **Fokas E**, O'Neill E, Gordon-Weeks A, Mukherjee S, McKenna WG, Muschel RJ. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. *Biochim Biophys Acta* 2015; **1855**: 61-82 [PMID: 25489989 DOI: 10.1016/j.bbcan.2014.12.001]

44 **Krishnan S**, Chadha AS, Suh Y, Chen HC, Rao A, Das P, Minsky BD, Mahmood U, Delclos ME, Sawakuchi GO, Beddar S, Katz MH, Fleming JB, Javle MM, Varadhachary GR, Wolff RA, Crane CH. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. *Int J Radiat Oncol Biol Phys* 2016; **94**: 755-765 [PMID: 26972648 DOI: 10.1016/j.ijrobp.2015.12.003]

45 **Koong AC**, Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK, Kee S, Trueblood W, Yang G, Bastidas JA. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2004; **58**: 1017-1021 [PMID: 15001240 DOI: 10.1016/j.ijrobp.2003.11.004]

46 **Hoyer M**, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Kiil Berthelsen A, Eberholst F, Engelholm SA, von der Maase H. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. *Radiother Oncol* 2005; **76**: 48-53 [PMID: 15990186 DOI: 10.1016/j.radonc.2004.12.022]

47 **Schellenberg D**, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2008; **72**: 678-686 [PMID: 18395362 DOI: 10.1016/j.ijrobp.2008.01.051]

48 **Chang DT**, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. *Cancer* 2009; **115**: 665-672 [PMID: 19117351 DOI: 10.1002/cncr.24059]

49 **Polistina F**, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. *Ann Surg Oncol* 2010; **17**: 2092-2101 [PMID: 20224860 DOI: 10.1245/s10434-010-1019-y]

50 **Rwigema JC**, Parikh SD, Heron DE, Howell M, Zeh H, Moser AJ, Bahary N, Quinn A, Burton SA. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. *Am J Clin Oncol* 2011; **34**: 63-69 [PMID: 20308870 DOI: 10.1097/COC.0b013e3181d270b4]

51 **Goyal K**, Einstein D, Ibarra RA, Yao M, Kunos C, Ellis R, Brindle J, Singh D, Hardacre J, Zhang Y, Fabians J, Funkhouser G, Machtay M, Sanabria JR. Stereotactic body radiation therapy for nonresectable tumors of the pancreas. *J Surg Res* 2012; **174**: 319-325 [PMID: 21937061 DOI: 10.1016/j.jss.2011.07.044]

52 **Gurka MK**, Collins SP, Slack R, Tse G, Charabaty A, Ley L, Berzcel L, Lei S, Suy S, Haddad N, Jha R, Johnson CD, Jackson P, Marshall JL, Pishvaian MJ. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. *Radiat Oncol* 2013; **8**: 44 [PMID: 23452509 DOI: 10.1186/1748-717X-8-44]

53 **Tozzi A**, Comito T, Alongi F, Navarria P, Iftode C, Mancosu P, Reggiori G, Clerici E, Rimassa L, Zerbi A, Fogliata A, Cozzi L, Tomatis S, Scorsetti M. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. *Radiat Oncol* 2013; **8**: 148 [PMID: 23799996 DOI: 10.1186/1748-717X-8-148]

54 **Herman JM**, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, Iacobuzio-Donahue CA, Griffith ME, Pawlik TM, Pai JS, O'Reilly E, Fisher GA, Wild AT, Rosati LM, Zheng L, Wolfgang CL, Laheru DA, Columbo LA, Sugar EA, Koong AC. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. *Cancer* 2015; **121**: 1128-1137 [PMID: 25538019 DOI: 10.1002/cncr.29161]

55 **Lin JC**, Jen YM, Li MH, Chao HL, Tsai JT. Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer. *Eur J Gastroenterol Hepatol* 2015; **27**: 259-264 [PMID: 25629569 DOI: 10.1097/MEG.0000000000000283]

56 **Mellon EA**, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. *Acta Oncol* 2015; **54**: 979-985 [PMID: 25734581 DOI: 10.3109/0284186X.2015.1004367]

57 **Comito T**, Cozzi L, Clerici E, Franzese C, Tozzi A, Iftode C, Navarria P, D'Agostino G, Rimassa L, Carnaghi C, Personeni N, Tronconi MC, De Rose F, Franceschini D, Ascolese AM, Fogliata A, Tomatis S, Santoro A, Zerbi A, Scorsetti M. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. *Technol Cancer Res Treat* 2017; **16**: 295-301 [PMID: 27311310 DOI: 10.1177/1533034616650778]

58 **Gurka MK**, Kim C, He AR, Charabaty A, Haddad N, Turocy J, Johnson L, Jackson P, Weiner LM, Marshall JL, Collins SP, Pishvaian MJ, Unger K. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. *Am J Clin Oncol* 2017; **40**: 152-157 [PMID: 25171298 DOI: 10.1097/COC.0000000000000118]

59 **Mazzola R**, Fersino S, Aiello D, Gregucci F, Tebano U, Corradini S, Di Paola G, Cirillo M, Tondulli L, Ruffo G, Ruggieri R, Alongi F. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. *Strahlenther Onkol* 2018; **194**: 835-842 [PMID: 29696321 DOI: 10.1007/s00066-018-1306-2]

60 **Orecchia R**, Surgo A, Muto M, Ferrari A, Piperno G, Gerardi MA, Comi S, Garibaldi C, Ciardo D, Bazani A, Golino F, Pansini F, Fodor C, Romanelli P, Maestri D, Scroffi V, Mazza S, Jereczek-Fossa BA. VERO® radiotherapy for low burden cancer: 789 patients with 957 Lesions. *Ecancermedicalscience* 2016; **10**: 677 [PMID: 27729942 DOI: 10.3332/ecancer.2016.677]

61 **Meduri B**, Gregucci F, D'Angelo E, Alitto AR, Ciurlia E, Desideri I, Marino L, Borghetti P, Fiore M, Fiorentino A; AIRO Giovani -Italian Association of Radiation Oncology-Young Members. Volume de-escalation in radiation therapy: state of the art and new perspectives. *J Cancer Res Clin Oncol* 2020; **146**: 909-924 [PMID: 32072318 DOI: 10.1007/s00432-020-03152-7]

62 **Stauder MC**, Miller RC. Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma. *Cancers (Basel)* 2010; **2**: 1565-1575 [PMID: 24281173 DOI: 10.3390/cancers2031565]

63 **Zhong J**, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, Patel PR, Kooby D, Landry J. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy *vs* conventionally fractionated radiation. *Cancer* 2017; **123**: 3486-3493 [PMID: 28493288 DOI: 10.1002/cncr.30706]

64 **Pflughoeft KJ**, Versalovic J. Human microbiome in health and disease. *Annu Rev Pathol* 2012; **7**: 99-122 [PMID: 21910623 DOI: 10.1146/annurev-pathol-011811-132421]

65 **Lepage P**, Leclerc MC, Joossens M, Mondot S, Blottière HM, Raes J, Ehrlich D, Doré J. A metagenomic insight into our gut's microbiome. *Gut* 2013; **62**: 146-158 [PMID: 22525886 DOI: 10.1136/gutjnl-2011-301805]

**Footnotes**

**Conflict-of-interest statement:** The authors state that they have no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 22, 2021

**First decision:** June 16, 2021

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Greece

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Carloni R, Ogino S **S-Editor:** Gao CC **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Pancreatic cancer percutaneous irreversible electroporation.** A: Axial computed tomography (CT) showing 2 cm lesion (red arrow) in the body of the pancreas in keeping with ductal adenocarcinoma; B and C: 3D volume rendering CT with parallel needles positioning within the lesion; D: 1-mo CT follow up showing complete ablation of the tumor (white arrow).



**Figure 2 Radiation treatment plan for a patient treated with stereotactic body radiotherapy for local advanced pancreatic cancer.** A-C: The plans show isodose levels in the axial plane (A), coronal plane (B), and sagittal plane (C).